AURORA CANNABIS INC (ACB)
CA05156X8504 - Common Stock
We assign a fundamental rating of 3 out of 10 to ACB. ACB was compared to 198 industry peers in the Pharmaceuticals industry. ACB has a bad profitability rating. Also its financial health evaluation is rather negative. ACB shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
ACB had negative earnings in the past year.
In the past year ACB has reported a negative cash flow from operations.
In the past 5 years ACB reported 4 times negative net income.
In the past 5 years ACB always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of ACB (-16.39%) is better than 66.67% of its industry peers.
ACB's Return On Equity of -25.93% is fine compared to the rest of the industry. ACB outperforms 70.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.39% | ||
| ROE | -25.93% | ||
| ROIC | N/A |
ROA(3y)-101.01%
ROA(5y)-60.91%
ROE(3y)-148.74%
ROE(5y)-89.66%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of ACB (1.93%) is comparable to the rest of the industry.
The Profit Margin and Operating Margin are not available for ACB so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 1.93% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ACB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ACB has more shares outstanding
The number of shares outstanding for ACB has been reduced compared to 5 years ago.
Compared to 1 year ago, ACB has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -10.11, we must say that ACB is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -10.11, ACB is not doing good in the industry: 75.90% of the companies in the same industry are doing better.
ACB has a Debt/Equity ratio of 0.15. This is a healthy value indicating a solid balance between debt and equity.
ACB has a Debt to Equity ratio of 0.15. This is comparable to the rest of the industry: ACB outperforms 46.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.15 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -10.11 |
ROIC/WACCN/A
WACC8.7%
2.3 Liquidity
A Current Ratio of 3.79 indicates that ACB has no problem at all paying its short term obligations.
ACB has a Current ratio (3.79) which is comparable to the rest of the industry.
A Quick Ratio of 2.45 indicates that ACB has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.45, ACB is in line with its industry, outperforming 45.13% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.79 | ||
| Quick Ratio | 2.45 |
3. Growth
3.1 Past
ACB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 80.02%, which is quite impressive.
ACB shows a strong growth in Revenue. In the last year, the Revenue has grown by 26.17%.
ACB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 65.00% yearly.
EPS 1Y (TTM)80.02%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-108.33%
Revenue 1Y (TTM)26.17%
Revenue growth 3Y-3.39%
Revenue growth 5Y65%
Revenue growth Q2Q4.44%
3.2 Future
The Earnings Per Share is expected to grow by 17.14% on average over the next years. This is quite good.
ACB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.02% yearly.
EPS Next Y-101.18%
EPS Next 2Y14.46%
EPS Next 3Y29.38%
EPS Next 5Y17.14%
Revenue Next Year55.98%
Revenue Next 2Y35.29%
Revenue Next 3Y27.89%
Revenue Next 5Y21.02%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ACB. In the last year negative earnings were reported.
Also next year ACB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ACB's earnings are expected to grow with 29.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.46%
EPS Next 3Y29.38%
5. Dividend
5.1 Amount
No dividends for ACB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AURORA CANNABIS INC
NASDAQ:ACB (4/24/2024, 6:00:05 PM)
After market: 7.11 -0.09 (-1.25%)7.2
-0.22 (-2.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap113.23M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.39% | ||
| ROE | -25.93% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 1.93% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.15 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.79 | ||
| Quick Ratio | 2.45 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)80.02%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-101.18%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)26.17%
Revenue growth 3Y-3.39%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y